Editorial Comment

Affiliations

Editorial

Allison M May et al. J Urol. 2023 May.

. 2023 May;209(5):899-900.

doi: 10.1097/JU.0000000000003195.01. Epub 2023 Apr 7.

No abstract available

Comment in

Reply by Authors.
Tyson MD, Morris D, Palou J, Rodriguez O, Mir MC, Dickstein RJ, Guerrero-Ramos F, Scarpato KR, Hafron JM, Messing EM, Cutie CJ, Maffeo JC, Raybold B, Chau A, Stromberg KA, Keegan KA. Tyson MD, et al. J Urol. 2023 May;209(5):900. doi: 10.1097/JU.0000000000003195.02. Epub 2023 Apr 7. J Urol. 2023. PMID: 37026638 No abstract available.

Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.
Tyson MD, Morris D, Palou J, Rodriguez O, Mir MC, Dickstein RJ, Guerrero-Ramos F, Scarpato KR, Hafron JM, Messing EM, Cutie CJ, Maffeo JC, Raybold B, Chau A, Stromberg KA, Keegan KA. Tyson MD, et al. J Urol. 2023 May;209(5):890-900. doi: 10.1097/JU.0000000000003195. Epub 2023 Apr 7. J Urol. 2023. PMID: 37026631 Clinical Trial.